Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Witzel

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 12, 2021
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter studyPetra Steinacker, Emily Feneberg, Steffen Halbgebauer, et al.
Annals of Neurology|August 9, 2025
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral SclerosisChristina Steffke, Karthik Baskar, Franziska Bachhuber, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 12, 2021
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter studyPetra Steinacker, Emily Feneberg, Steffen Halbgebauer, et al.
Annals of Neurology|August 9, 2025
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral SclerosisChristina Steffke, Karthik Baskar, Franziska Bachhuber, et al.
Eclinicalmedicine|February 22, 2024
Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access programMaximilian Wiesenfarth, Johannes Dorst, David Brenner, et al.
Pageof 4